Spencer Vaughn

CSL Seqirus

CSL Seqirus, a business unit of CSL, was created from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis. In July 2015, the two businesses joined forces to create CSL Seqirus, now the second largest influenza vaccine company in the world. With extensive research and production expertise and manufacturing plants in the US, UK, Germany and Australia, CSL Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally. CSL Seqirus has a workforce of over 3,000 employees, significant manufacturing capacity and a commercial presence in over 20 countries. In Australia and New Zealand, CSL Seqirus markets a comprehensive range of vaccines and specialty pharmaceutical products. It also manufactures products of national significance for Australia, including antivenoms and Q fever vaccine. See our community guidelines: https://bit.ly/3QZbZeZ